Nefazodone
WikiDoc Resources for Nefazodone |
Articles |
---|
Most recent articles on Nefazodone |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Nefazodone at Clinical Trials.gov Clinical Trials on Nefazodone at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Nefazodone
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Nefazodone Discussion groups on Nefazodone Patient Handouts on Nefazodone Directions to Hospitals Treating Nefazodone Risk calculators and risk factors for Nefazodone
|
Healthcare Provider Resources |
Causes & Risk Factors for Nefazodone |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Synonyms / Brand Names: Nefazodona, Nefazodone Hcl, Nefazodone hydrochloride, Nefazodonum, Dutonin, Serzone
Dosing and Administration
The recommended starting dose for Nefazodone hydrochloride tablets is 200 mg/day, administered in two divided doses (BID). In the controlled clinical trials establishing the antidepressant efficacy of Nefazodone, the effective dose range was generally 300 to 600 mg/day. Consequently, most patients, depending on tolerability and the need for further clinical effect, should have their dose increased. Dose increases should occur in increments of 100 mg/day to 200 mg/day, again on a BID schedule, at intervals of no less than 1 week. As with all antidepressants, several weeks on treatment may be required to obtain a full antidepressant response.
Adapted from the FDA Package Insert. Template:WH